The Latest Breaking News from Biogen Inc

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

Cooling inflation data and Fed’s recent 25 bps rate hike have contributed considerably to optimistic investor sentiment in the past few weeks. However, as opposed to an expected pause, the robust jobs report has raised prospects of further rate hikes in the coming months. Therefore, it could be wise to…

Although macroeconomic headwinds kept the stock market under immense pressure last year, the declining inflation rates have increased investor optimism recently. Hence, quality Nasdaq stocks Comcast Corporation (CMCSA), Honeywell International (HON), and Biogen (BIIB) might be solid buys this year. Read on….

Increased government initiatives and the rising adoption of biotechnology in healthcare and agriculture are likely to enhance the growth of the biotech industry. Hence, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Jazz Pharmaceuticals (JAZZ) might be ideal additions to your portfolio as they look well-positioned to capitalize…

With the Fed slated to increase rates aggressively this year to curb inflation, value stocks could shine again. Thus, investors could invest in shares of fundamentally strong stocks Biogen (BIIB), Dow Inc. (DOW), and Albertsons Companies (ACI) that are trading at attractive valuations. Continue reading….

While inflation eased considerably for two consecutive months, the Fed signaled to keep raising interest rates through this year. The potential continuation of rate hikes has fueled recessionary concerns. Amid an uncertain macroeconomic backdrop, it could be wise to buy fundamentally strong stocks Merck (MRK), Biogen (BIIB), and MasterCraft Boat…

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

Legendary investor Warren Buffett’s holding company Berkshire Hathaway has outperformed the broader market over the past year. His investment portfolio has been a guide for several long-term investors for decades. Amid a highly uncertain market and economic backdrop, Warren Buffett holdings Procter & Gamble (PG), AbbVie (ABBV), Biogen (BIIB), and…

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…